Latest news
Survodutide’s Phase III data raise a bigger question than weight loss
Phase III SYNCHRONIZE-2 data show that the investigational glucagon/GLP-1 dual agonist survodutide can reduce body weight and improve glycaemic control in people with obesity and type 2 diabetes
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
China’s Biliary-Cancer Bet Has a Global Access Problem
Alzheimer’s Trials Are Finally Blood-Gated
MS Regulators Are No Longer Reading the Same Risk
NTDs Are Now A Human-Rights Issue. Budgets Must Follow.
Europe Can Forecast Vibrio Risk. It Still Has To Act.
Cardiology has too many dashboards. The danger is forgetting the patient
GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
A CE Mark Is Not Access
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.